Akebia Ther (AKBA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $131.67M
Last updated: Nov 17, 2026 at 4:38 PM ET
Akebia Ther (AKBA) Statistics
Akebia Ther (AKBA) has a market cap of $131.67M and an enterprise value of $22.68M. It holds $108.98M more cash than debt, 82.77% of its market cap. Its share count is up 4.56% from a year earlier.
Total Valuation
Enterprise value is 82.77% below the market cap, as cash exceeds debt.
| Market Cap | $131.67M |
|---|---|
| Enterprise Value | $22.68M |
| Latest price (Nov 17, 2026) | $0.40 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.6x and 5.4x. Its year-end P/S ranged from 1.2x to 262.9x from 2016 to 2025.
| P/S Ratio | 0.6x |
|---|---|
| Forward P/S | 0.8x |
| P/B Ratio | 5.4x |
| P/FCF Ratio | 8.0x |
| P/OCF Ratio | 8.3x |
Enterprise Valuation
Counting debt and cash, the company is valued at 0.1x free cash flow.
| EV / Sales | 0.1x |
|---|---|
| EV / FCF | 0.1x |
Price Statistics
The stock is down 76.02% over 52 weeks and trades 46.67% below its 50-day average.
| Beta (1Y) | 2.78 |
|---|---|
| 52-Week Change | -76.02% |
| 1-Month Change | -41.13% |
| 3-Month Change | -54.78% |
| 6-Month Change | -55.27% |
| 5-Year Change | -75.38% |
| 10-Year Change | -90.61% |
| Total Return (1Y) | -76.02% |
| Total Return (3Y CAGR) | -26.29% |
| Total Return (5Y CAGR) | -32.05% |
| Max Drawdown (1Y) | -77.25% |
| Max Drawdown (3Y) | -90.01% |
| Sharpe Ratio (1Y) | -1.50 |
| Correlation with SPY (1Y) | 0.40 |
| 50-Day Average | $0.75 |
| 200-Day Average | $1.09 |
| 52-Week Range | $0.36 to $1.73 |
| RSI (14 Days) | 32.5 |
| Average Volume (20 Days) | 8.60M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.36x current liabilities, and total debt is 2.47x shareholder equity.
| Current Ratio | 1.36x |
|---|---|
| Quick Ratio | 1.24x |
| Debt / Equity | 2.47x |
| Debt / FCF | 3.63x |
Returns and Efficiency
Return on invested capital is -38.86% and return on equity is -218.76% over the last 12 months.
| Return on Equity (ROE) | -218.76% |
|---|---|
| Return on Assets (ROA) | -13.02% |
| Return on Invested Capital (ROIC) | -38.86% |
| Return on Capital Employed (ROCE) | -15.27% |
| ROA (5Y Average) | -26.82% |
| Asset Turnover | 0.56x |
| Inventory Turnover | 2.62x |
| Receivables Turnover | 4.38x |
| Cash Conversion Cycle | 148 days |
Scores
AKBA has an Altman Z-Score of -6.30, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -6.30 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $197.20M over the last 12 months is down 12.38% from the 12 months before.
| Revenue | $197.20M |
|---|---|
| Revenue Growth (YoY) | -12.38% |
| Gross Profit | $155.59M |
| Operating Income | -$31.04M |
| Pretax Income | -$43.18M |
| Net Income | -$44.56M |
| EBITDA | -$26.11M |
| EBIT | -$27.45M |
| Reported EPS (TTM) | -$0.14 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 5.95% of the $342.13M in total assets.
| Cash and Equivalents | $159.25M |
|---|---|
| Total Debt | $50.27M |
| Net Cash | $108.98M |
| Net Cash Per Share | $0.39 |
| Working Capital | $58.44M |
| Shareholder Equity | $20.37M |
| Book Value Per Share | $0.07 |
| Tangible Book Value | -$38.67M |
| Total Assets | $342.13M |
| Total Liabilities | $321.76M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.92M of capital spending, operating cash flow left $13.86M of free cash flow.
| Operating Cash Flow | $15.78M |
|---|---|
| Capital Expenditures | $1.92M |
| Free Cash Flow | $13.86M |
| FCF Per Share | $0.05 |
| Depreciation and Amortization | $1.33M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -15.74%, against a 5-year average of -39.58%.
| Gross Margin | 78.90% |
|---|---|
| Operating Margin | -15.74% |
| Pretax Margin | -21.90% |
| Net Margin | -22.60% |
| EBITDA Margin | -13.24% |
| EBIT Margin | -13.92% |
| FCF Margin | 7.03% |
| Gross Margin (5Y Average) | 61.06% |
| Operating Margin (5Y Average) | -39.58% |
| Net Margin (5Y Average) | -47.55% |
Growth
Revenue fell 6.88% a year over 3 years.
| Revenue Growth (3Y CAGR) | -6.88% |
|---|---|
| Revenue Growth (5Y CAGR) | -4.33% |
Dividends and Yields
AKBA does not pay a dividend. Its free cash flow yield is 12.50%.
| FCF Yield | 12.50% |
|---|---|
| Buyback Yield | -9.04% |
| Shareholder Yield | -9.04% |
Peer Position
Against 8 similar companies, AKBA has the 6th highest P/S.
P/S RatioPeer median 1.5x
ROICPeer median -3.84%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.40%
| P/S Ratio | 0.6x vs 1.5x median |
|---|---|
| ROIC | -38.86% vs -3.84% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -12.38% vs +11.40% median |
Analyst Forecast
Consensus estimates put revenue growth at -33.47% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -33.47% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About AKBA
What is AKBA's market cap?
Akebia Ther has a market cap of $131.67M. Its enterprise value, which adds debt and subtracts cash, is $22.68M.
How many shares of AKBA are outstanding?
Akebia Ther has 276.86M shares outstanding. The count is up 4.56% from a year earlier.
Does AKBA pay a dividend?
No. Akebia Ther does not pay a dividend.
How much debt does AKBA have?
Akebia Ther has $50.27M of total debt and $159.25M of cash and equivalents, a net cash position of $108.98M.
AKBA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors